Get the Stockscreener App
9.15
11.31%
0.93
Pre-market:
9.19
0.04
+0.44%
Quantum Biopharma Ltd stock is traded at $9.15, with a volume of 88,493.
It is up +11.31% in the last 24 hours and up +45.24% over the past month.
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.
See More
Previous Close:
$8.22
Open:
$8.27
24h Volume:
88,493
Relative Volume:
0.16
Market Cap:
$24.80M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.69%
1M Performance:
+45.24%
6M Performance:
+77.33%
1Y Performance:
+0.00%
1-Day Range:
$8.06
$9.15
1-Week Range:
$7.961
$9.45
52-Week Range:
$2.70
$18.00
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
9.15 | 2.61M | 0 | 0 | 0 | 0.00 |
|
HLN
Haleon Plc Adr
|
10.67 | 47.63B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
160.35 | 71.99B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.81 | 3.50M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.00 | 44.91B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.87 | 20.73B | 16.54B | -1.64B | 749.00M | -1.45 |
Quantum Biopharma Ltd Stock (QNTM) Latest News
Quantum Biopharma reports Q1 2025 financials - Investing.com
Quantum Biopharma reports Q1 2025 financials By Investing.com - Investing.com Nigeria
Quantum Biopharma Reports Q1 2025 Financial Results - TipRanks
Quantum BioPharma (QNTM) Completes Key Studies for Multiple Scle - GuruFocus
Quantum BioPharma Completes Key Studies for MS Drug Lucid-MS - TipRanks
Quantum BioPharma Completes Dosing in 90-Day Toxicity Studies for Multiple Sclerosis Drug Lucid-21-302, Advancing Toward IND Submission - Nasdaq
Quantum BioPharma Announces Completion of Dosing in 90-Day - GlobeNewswire
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis - Welland Tribune
Quantum BioPharma Ltd. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:QNTM) - Seeking Alpha
Quantum Biopharma Files Amended Complaint Against CIBC - GlobeNewswire
Quantum BioPharma (QNTM) Files Amended Complaint Over Alleged Ma - GuruFocus
Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing - The Manila Times
Quantum Biopharma Ltd. Approved to Dual List on Upstream - ACCESS Newswire
Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Quantum BioPharma to Reveal Year-End Results and Key Regulatory Milestones in May 6 Update - Stock Titan
Quantum BioPharma Ltd. to Host Business Update Conference Call on May 6, 2025 - Nasdaq
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time - GlobeNewswire
Quantum BioPharma adds Kevin Malone as advisor - Investing.com Australia
Quantum BioPharma adds Kevin Malone as advisor By Investing.com - Investing.com South Africa
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor - The Manila Times
Quantum Biopharma Announces Advocate Against Naked Short - GlobeNewswire
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin ... - Bluefield Daily Telegraph
Quantum BioPharma Strengthens Defense: Short Selling Expert Kevin Malone to Combat Market Manipulation - Stock Titan
Quantum BioPharma Announces RSU Grant and Debt Settlement - TipRanks
Quantum BioPharma Corporate Update - Newsfile
1 ‘Defensive’ Cathie Wood Stock to Buy While It’s at a ‘Great Entry Point’ - The Globe and Mail
West Fraser Timber Ltd Stock Analysis: Q1 2025 Earnings and Future Outlook - The Globe and Mail
Meta Platforms (META) Can Withstand an Advertising Slowdown, Says Citigroup - The Globe and Mail
Stocks Pressured by Fears of a Tariff-Induced Slowdown - The Globe and Mail
Why ServiceNow Stock Is Gaining Today - The Globe and Mail
What to Know About Jeff Bezos’ Secret EV Startup Slate Auto - The Globe and Mail
Allied Announces April 2025 Distribution - The Globe and Mail
Rocket Lab Stock (RKLB) Soars on Major Hypersonic Tech Deals with US and UK Governments - The Globe and Mail
Abbott Laboratories (ABT) Q1 Earnings: What To Expect - The Globe and Mail
BWXT Moving Forward to Support National Security, Domestic Uranium Enrichment Mission - The Globe and Mail
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhar - GuruFocus
Quantum BioPharma (QNTM) Prevails in Legal Dispute with Former C - GuruFocus
Lithium Argentina to Release First Quarter 2025 Results on May 14, 2025 - The Globe and Mail
Quantum BioPharma wins legal battle against former CEO By Investing.com - Investing.com South Africa
Market Analysis: April 14th, 2025 - The Globe and Mail
Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold - The Globe and Mail
3 Hot New IPOs Defying the 2025 Market Slump - The Globe and Mail
Canadian Insurance Market Remains Strong Amidst Market Volatility: Aon Report - The Globe and Mail
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 to Ignore - The Globe and Mail
Quantum BioPharma Secures Legal Victory with $180,000 Award - TipRanks
Quantum BioPharma wins legal battle against former CEO - Investing.com
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario - GlobeNewswire
Latest: Court Upholds $2.8M Award in Quantum BioPharma's Favor Against Former CEO - Stock Titan
2 AI Stocks That Could Help Set You Up for Life - The Globe and Mail
3 ETFs to Save Your Portfolio Right Now - The Globe and Mail
Quantum Biopharma Ltd Stock (QNTM) Financials Data
There is no financial data for Quantum Biopharma Ltd (QNTM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
4.39%
1.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):